Literature DB >> 18160720

Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Megumi Funakoshi-Tago1, Stéphane Pelletier, Hiroshi Moritake, Evan Parganas, James N Ihle.   

Abstract

Janus kinases are essential for signal transduction by a variety of cytokine receptors and when inappropriately activated can cause hematopoietic disorders and oncogenesis. Consequently, it can be predicted that the interaction of the kinases with receptors and the events required for activation are highly controlled. In a screen to identify phosphorylation events regulating Jak2 activity in EpoR signaling, we identified a mutant (Jak2-Y613E) which has the property of being constitutively activated, as well as an inactivating mutation (Y766E). Although no evidence was obtained to indicate that either site is phosphorylated in signaling, the consequences of the Y613E mutation are similar to those observed with recently described activating mutations in Jak2 (Jak2-V617F and Jak2-L611S). However, unlike the V617F or L611S mutant, the Y613E mutant requires the presence of the receptor but not Epo stimulation for activation and downstream signaling. The properties of the Jak2-Y613E mutant suggest that under normal conditions, Jak2 that is not associated with a receptor is locked into an inactive state and receptor binding through the FERM domain relieves steric constraints, allowing the potential to be activated with receptor engagement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160720      PMCID: PMC2258779          DOI: 10.1128/MCB.01447-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

Review 1.  Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP.

Authors:  Annie Bourdeau; Nadia Dubé; Michel L Tremblay
Journal:  Curr Opin Cell Biol       Date:  2005-04       Impact factor: 8.382

Review 2.  Jak2: normal function and role in hematopoietic disorders.

Authors:  James N Ihle; D Gary Gilliland
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

3.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Authors:  Xiaohui Lu; Ross Levine; Wei Tong; Gerlinde Wernig; Yana Pikman; Sara Zarnegar; D Gary Gilliland; Harvey Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.

Authors:  Jason H Kurzer; Pipsa Saharinen; Olli Silvennoinen; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.

Authors:  Megumi Funakoshi-Tago; Stephane Pelletier; Tadashi Matsuda; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

7.  Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function.

Authors:  Stéphane Pelletier; Sébastien Gingras; Megumi Funakoshi-Tago; Sherié Howell; James N Ihle
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

8.  Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor.

Authors:  Anna M Mazurkiewicz-Munoz; Lawrence S Argetsinger; Jean-Louis K Kouadio; Allan Stensballe; Ole N Jensen; Joel M Cline; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

9.  Structural basis for the autoinhibition of focal adhesion kinase.

Authors:  Daniel Lietha; Xinming Cai; Derek F J Ceccarelli; Yiqun Li; Michael D Schaller; Michael J Eck
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

10.  Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling.

Authors:  Ryoko Ishida-Takahashi; Felicia Rosario; Yusong Gong; Keely Kopp; Zlatina Stancheva; Xiaohong Chen; Edward P Feener; Martin G Myers
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

View more
  33 in total

Review 1.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

2.  Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation.

Authors:  Kristy Boyle; Jian-Guo Zhang; Sandra E Nicholson; Evelyn Trounson; Jeffery J Babon; Edward J McManus; Nicos A Nicola; Lorraine Robb
Journal:  Cell Signal       Date:  2008-11-12       Impact factor: 4.315

3.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

4.  Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.

Authors:  Henrik M Hammarén; Anniina T Virtanen; Bobin George Abraham; Heidi Peussa; Stevan R Hubbard; Olli Silvennoinen
Journal:  J Allergy Clin Immunol       Date:  2018-08-06       Impact factor: 10.793

5.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

Review 6.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

Authors:  Wanlong Ma; Hagop Kantarjian; Xi Zhang; Xiuqiang Wang; Zhong Zhang; Chen-Hsiung Yeh; Susan O'Brien; Francis Giles; Jean Marie Bruey; Maher Albitar
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

8.  The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Kazuya Sumi; Miyuki Abe; Eriko Aizu-Yokota; Tomoyuki Oshio; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

Review 9.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage.

Authors:  Constance Tom Noguchi; Li Wang; Heather M Rogers; Ruifeng Teng; Yi Jia
Journal:  Expert Rev Mol Med       Date:  2008-12-01       Impact factor: 5.600

Review 10.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.